Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,067.50
    +739.36 (+1.44%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Sweden's Cellink to buy U.S in-vitro company MatTek in $68 million deal

Reuters
·1-min read

STOCKHOLM (Reuters) - Swedish bioconvergence company Cellink has agreed to buy U.S.-based in-vitro technology firm MatTek for $68 million, Cellink said on Wednesday.

The company said it would pay 20% of the purchase price in newly issued B-shares and the rest in cash.

It said in a statement that by combining the two firms it would be able to offer market leading in-vitro methods and "finally replace controversial animal tests that are limited by their physiological relevance to predict human results".

WATCH: How to save money on a low income

Cellink, which develops technologies to culture cells in 3D, perform drug screening and print human tissues and organs, added that it was expecting the deal to close by March 24, provided that all conditions were met.

MatTek had revenues of $16.6 million in 2020.

WATCH: How to prevent getting into debt

(Reporting by Helena Soderpalm, editing by Anna Ringstrom)